NewLink Genetics Corp Rating Reiterated by Stifel Nicolaus (NLNK)
NewLink Genetics Corp (NASDAQ:NLNK)‘s stock had its “buy” rating restated by equities research analysts at Stifel Nicolaus in a research note issued to investors on Wednesday, Analyst Ratings Network reports. They currently have a $51.00 price target on the stock, down from their previous price target of $53.00. Stifel Nicolaus’ price target points to a potential upside of 135.24% from the company’s current price.
A number of other analysts have also recently weighed in on NLNK. Analysts at Robert W. Baird cut their price target on shares of NewLink Genetics Corp from $40.00 to $29.00 in a research note on Wednesday, April 9th. Separately, analysts at MLV & Co
raised their price target on shares of NewLink Genetics Corp from $29.00 to $45.00 in a research note on Monday, March 31st. They now have a “buy” rating on the stock. Finally, analysts at Jefferies Group raised their price target on shares of NewLink Genetics Corp from $29.00 to $36.00 in a research note on Wednesday, March 12th. Two analysts have rated the stock with a buy rating, NewLink Genetics Corp presently has a consensus rating of “Buy” and a consensus target price of $39.00.
NewLink Genetics Corp (NASDAQ:NLNK) traded up 0.09% on Wednesday, hitting $21.68. 314,222 shares of the company’s stock traded hands. NewLink Genetics Corp has a 52 week low of $14.41 and a 52 week high of $53.48. The stock has a 50-day moving average of $24.20 and a 200-day moving average of $26.67. The company’s market cap is $604.0 million.
NewLink Genetics Corp (NASDAQ:NLNK) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.04. On average, analysts predict that NewLink Genetics Corp will post $-1.71 earnings per share for the current fiscal year.
NewLink Genetics Corporation operates as a biopharmaceutical company. The Company, based in the United States, is focused on discovering, developing, and commercializing immunotherapeutic products to improve cancer treatment options for patients and physicians.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.